Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)
by Renee Jackson · The Cerbat GemRepresentative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). In a filing disclosed on January 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Agios Pharmaceuticals stock on December 11th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.
Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):
- Sold $1,001 – $15,000 in shares of Xiaomi (OTCMKTS:XIACF) on 12/30/2025.
- Sold $1,001 – $15,000 in shares of Schneider Electric S.E. (OTCMKTS:SBGSF) on 12/30/2025.
- Sold $1,001 – $15,000 in shares of Hermès International Société en commandite par actions (OTCMKTS:HESAF) on 12/30/2025.
- Purchased $50,001 – $100,000 in shares of Campbell’s (NASDAQ:CPB) on 12/30/2025.
- Sold $1,001 – $15,000 in shares of Tencent (OTC:TCTZF) on 12/30/2025.
- Sold $1,001 – $15,000 in shares of Mitsubishi Heavy Industries (OTCMKTS:MHVYF) on 12/26/2025.
- Sold $1,001 – $15,000 in shares of Bloom Energy (NYSE:BE) on 12/24/2025.
- Sold $1,001 – $15,000 in shares of Arista Networks (NYSE:ANET) on 12/24/2025.
- Sold $1,001 – $15,000 in shares of Coinbase Global (NASDAQ:COIN) on 12/24/2025.
- Sold $1,001 – $15,000 in shares of Chevron (NYSE:CVX) on 12/24/2025.
Agios Pharmaceuticals Stock Up 3.3%
Shares of AGIO traded up $0.93 during mid-day trading on Wednesday, hitting $28.73. The stock had a trading volume of 769,200 shares, compared to its average volume of 982,378. Agios Pharmaceuticals, Inc. has a fifty-two week low of $22.24 and a fifty-two week high of $46.00. The company has a market cap of $1.68 billion, a PE ratio of -4.10 and a beta of 0.89. The company’s fifty day simple moving average is $30.22 and its two-hundred day simple moving average is $35.69.
Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.78) EPS for the quarter, topping analysts’ consensus estimates of ($1.93) by $0.15. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. The firm had revenue of $12.88 million during the quarter, compared to the consensus estimate of $10.49 million. During the same quarter in the previous year, the company posted $16.22 earnings per share. The firm’s revenue was up 43.3% on a year-over-year basis. Equities analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.
Institutional Investors Weigh In On Agios Pharmaceuticals
Hedge funds and other institutional investors have recently bought and sold shares of the business. NewEdge Advisors LLC bought a new position in shares of Agios Pharmaceuticals in the 1st quarter valued at about $40,000. First Horizon Corp bought a new position in Agios Pharmaceuticals in the third quarter valued at approximately $45,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Agios Pharmaceuticals by 16.7% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 320 shares during the last quarter. Quantbot Technologies LP acquired a new stake in Agios Pharmaceuticals during the 3rd quarter worth $79,000. Finally, Acadian Asset Management LLC bought a new stake in shares of Agios Pharmaceuticals during the 1st quarter valued at $133,000.
Analyst Ratings Changes
AGIO has been the subject of several recent analyst reports. Royal Bank Of Canada cut shares of Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and decreased their target price for the stock from $57.00 to $28.00 in a report on Wednesday, November 19th. Leerink Partners upped their price target on Agios Pharmaceuticals from $34.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday, December 26th. Zacks Research upgraded shares of Agios Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 4th. Leerink Partnrs upgraded Agios Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 20th. Finally, Citigroup reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a research report on Friday, December 26th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Agios Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $39.44.
Insiders Place Their Bets
In related news, CEO Brian Goff sold 18,703 shares of Agios Pharmaceuticals stock in a transaction on Tuesday, December 30th. The stock was sold at an average price of $27.09, for a total transaction of $506,664.27. Following the completion of the sale, the chief executive officer directly owned 136,583 shares of the company’s stock, valued at $3,700,033.47. The trade was a 12.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Sarah Gheuens sold 3,302 shares of the firm’s stock in a transaction dated Monday, October 27th. The stock was sold at an average price of $43.92, for a total value of $145,023.84. Following the sale, the insider directly owned 61,727 shares in the company, valued at approximately $2,711,049.84. This represents a 5.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 37,005 shares of company stock worth $1,064,531 over the last three months. Insiders own 4.93% of the company’s stock.
About Representative Cisneros
Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.
Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.
Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.